Please assess the completion status of the following clinical trial:

Trial Title: An Efficacy Trial of Low Dose All-trans Retinoic Acid in Patients With Primary Sclerosing Cholangitis

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Males and females ages 18-80~* Diagnosis of large-duct PSC based on ERCP or MRCP, or liver biopsy findings without alternative explanation for findings, for at least 6 months.~* Serum ALP levels persistently more than 1.5 x upper limit of normal over the past 6 months.~* Ursodeoxycholic acid therapy must be discontinued for at least 3 months.~* At least 2 forms of barrier protection for males and females of child-bearing age.~Exclusion Criteria:~* Small duct PSC, overlap with autoimmune hepatitis, IgG4 disease or secondary sclerosing cholangitis.~* Any malignancy, presently or within the past 5 years, except adequately treated non-melanoma skin cancer, carcinoma in situ of the cervix or in situ prostate cancer.~* Viral hepatitis including hepatitis A, B, C, D, E.~* Decompensated cirrhosis, or planned liver transplantation.~* Recent diagnostic or therapeutic biliary manipulation (endoscopic, radiologic) within the past 3 months.~* Ascending Cholangitis requiring antibiotics within the past 3 months.~* Uncontrolled IBD, or IBD requiring the use of steroids.~* Acute or Chronic Kidney Disease with serum creatinine \> 2 mg/dL.~* Allergy to ATRA or vitamin A compounds.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- All-trans retinoic acid (ATRA) therapy (Type: EXPERIMENTAL): Fixed low dose of ATRA 10 mg twice daily for 24 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).